Don’t let the high cost of brand chronic hepatitis B therapy disrupt your treatment. We help eligible patients access Hepsera (adefovir dipivoxil) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Hepsera Prescription Assistance Program is a manufacturer-sponsored initiative that provides Hepsera at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for chronic hepatitis B patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, hepatologist coordination, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens (brand) | ~$880.00 | Save ~$810/mo |
| CVS Pharmacy (brand) | ~$900.00 | Save ~$830/mo |
| Walmart (brand) | ~$750.00 | Save ~$680/mo |
| Costco (brand) | ~$720.00 | Save ~$650/mo |
| Generic adefovir | ~$60.00 | Already low |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Hepsera at no medication cost if approved. Our $69.95/month service covers full advocacy. With generic adefovir widely available — and current HBV guidelines preferring entecavir or tenofovir over adefovir — we’ll help you and your provider determine the best path.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Hepsera:
Still $700–$900 per month even with the best discount
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Hepsera assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Hepsera (adefovir dipivoxil) is a once-daily nucleotide analog used to treat chronic hepatitis B. It was one of the early HBV antivirals but has been largely replaced in current guidelines by more potent agents (entecavir, tenofovir TDF, tenofovir TAF) with lower rates of resistance.
How Hepsera Works:
Adefovir dipivoxil is a prodrug that converts into an active nucleotide analog to block the reverse transcriptase enzyme used by the Hepatitis B virus. Once inside liver cells, it competes with natural building blocks to integrate into the viral DNA chain, effectively terminating its growth and halting replication. While functional, it is considered moderately potent and slower-acting compared to newer antivirals, with a higher susceptibility to viral resistance.
Form and use:
Marketed as Hepsera, this medication is administered as a single 10 mg tablet taken orally once daily, regardless of food intake. Because the treatment is typically long-term, consistent monitoring of renal function is essential. Since adefovir can cause kidney injury, healthcare providers must adjust the dosage for patients with pre-existing or developing renal impairment.
Generic availability:
Generic adefovir dipivoxil is widely available and significantly more cost-effective than the brand-name Hepsera. Despite its availability, modern guidelines generally favor more potent options like entecavir or tenofovir, which have lower resistance rates. Adefovir is now primarily reserved for patients who have developed resistance to lamivudine or those who cannot tolerate preferred therapies.
Warnings:
Hepsera carries a boxed warning for severe acute HBV exacerbation if the medication is discontinued abruptly. It is not intended to treat HIV-1; therefore, HIV testing is mandatory before initiation to prevent the development of drug-resistant HIV. Other serious risks include potential nephrotoxicity, lactic acidosis, and severe liver enlargement with fatty deposits. effective and safe.
Brand Hepsera costs approximately $700–$900 per 30-day supply. Generic adefovir is dramatically cheaper, often $40–$80/month with a coupon. Through AffordMyPrescriptions, qualifying patients receive brand Hepsera at no medication cost — our $69.95 monthly fee covers full advocacy and program management. If generic adefovir or a different first-line agent is appropriate, we’ll help confirm the best path.
Current chronic HBV treatment guidelines prefer entecavir (generic available), tenofovir disoproxil fumarate (Viread, generic available), or tenofovir alafenamide (Vemlidy) over adefovir. The newer agents are more potent (achieve undetectable HBV DNA faster), have higher barriers to resistance (HBV develops resistance to entecavir or tenofovir very rarely), and have generally better safety profiles. Adefovir is now mostly used in specific scenarios such as documented resistance to other agents.
Discuss with your hepatologist or primary HBV provider. If you have been on Hepsera and HBV is suppressed, it may be reasonable to continue. But if you are starting therapy now or your HBV DNA remains detectable on Hepsera, switching to entecavir, tenofovir TDF, or tenofovir TAF is usually preferred.
Adefovir has weak activity against HIV at HBV doses. If you have undiagnosed HIV and start Hepsera alone, HIV could develop partial resistance to tenofovir-related compounds — limiting future HIV treatment. HIV testing is required before starting.
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays you cannot afford. Given the wide availability of generic adefovir, however, many Medicare patients can access adefovir at low cost without needing PAP
Hepsera can be nephrotoxic, especially at higher doses or in patients with pre-existing kidney disease. Dose adjustments are required for moderate to severe renal impairment. Your provider should monitor kidney function (serum creatinine and eGFR) regularly while you’re on Hepsera.
If denied, we explore alternatives — switching to generic adefovir, generic entecavir, generic tenofovir TDF, or Vemlidy (TAF), the manufacturer’s copay program for commercially insured patients, or independent foundations. If we cannot find a path, you won’t be charged our service fee.
If you are struggling with the high cost of Hepsera, our team may be able to help you access assistance programs — or guide you to generic adefovir, entecavir, or tenofovir if more appropriate. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.